Mr. Justin Renz reports

CORREVIO ANNOUNCES EU SURVEY DATA DEMONSTRATING BRINAVESS SUCCESSFULLY AVOIDED HOSPITALIZATION IN 85% OF PATIENTS

Correvio Pharma Corp. has provided positive data highlighting reduced hospitalization in patients treated with Brinavess (vernakalant hydrochloride, IV), its anti-arrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF in Belgian hospitals. As a result of this new, real-world data, Brinavess received reimbursement approval from the National Institute for Health and Disability Insurance (NIHDI) in Belgium.

The data from this survey, which was mandated by the NIHDI, were provided by six participating hospitals in Belgium, across a total of 97 patients that were treated with Brinavess in the emergency room setting for a total of 15.5 months during 2017 and 2018. The data demonstrated that treatment with Brinavess successfully avoided hospitalization for 85.4 per cent (95-per-cent confidence interval (CI) 76.1 to 94.8) of all treated patients. Treatment with Brinavess also significantly decreased the use of electric cardioversion, with 84.1 per cent (95 per cent CI 71.5 to 96.7) of patients avoiding electric cardioversion and all adverse events related to this procedure.

"These data provide important, real-world clinical information on the usage of Brinavess for the treatment of acute AF in the emergency room, in Belgium," said Kiran Bhirangi, MD, Correvio's vice-president, clinical development and medical affairs. "In this study, normal heart rhythm was restored in 85 per cent of patients, thereby avoiding electric cardioversion, its accompanying side effects and hospitalization. We believe Brinavess is an important treatment alternative for patients with recent onset AF, and particularly for those who will benefit from pharmacologic cardioversion."

"The reimbursement of Brinavess in Belgium is a key commercial development for this important treatment in one of the valuable European markets covered by our direct sales force and underscores its recognized pharmacoeconomic benefit," said Hugues Sachot, Correvio's chief commercial officer. "Our commercial team has been actively working with our hospital customers and we believe this approval will only enhance the adoption and uptake of Brinavess, a clinically and economically proven option for physicians treating patients in the acute hospital setting."

About atrial fibrillation

Atrial fibrillation (also known as AFib or AF) is a supraventricular tachyarrhythmia with uncoordinated atrial activation resulting in ineffective atrial contraction and if left untreated, structural and/or electrophysiological atrial tissue abnormalities (1). AF is a common cardiac rhythm disturbance that increases in prevalence with advancing age (1). According to the American Heart Association, estimates of the prevalence of AF in the United States ranged from 2.7 million to 6.1 million in 2010, and is expected to rise to between 5.6 million to 12 million in 2030 (2). The prevalence of AF in Chinese adults age 35 and above is estimated to be 0.74 per cent in males and 0.72 per cent in females, but the prevalence rises significantly for adults age 60 and above with the prevalence estimated to be 1.8 per cent in males and 1.9 per cent in females. With a population of greater than one billion, this translates to a significant market opportunity in China (3).

There are two strategies to manage AF, namely, rhythm or rate control. A rhythm-control strategy may be used in patients who are severely compromised, remain symptomatic despite adequate rate control, when adequate rate control is difficult to achieve, when long-term rhythm control therapy is preferred, younger patient age, presence of tachycardia-mediated cardiomyopathy, and first episode of AF (1) (4). Early intervention with a rhythm-control strategy to prevent progression of AF may be particularly beneficial to the AF patient (1).

About Brinavess

Brinavess (vernakalant HCl, IV) is an anti-arrhythmic drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion. Brinavess is approved for marketing in Europe, Canada and several other countries worldwide. In Europe, it is approved for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: 1) for non-surgery patients: atrial fibrillation/u greater than seven days duration; and 2) for postcardiac surgery patients: atrial fibrillation/u greater than days duration. Vernakalant IV is not approved for use in the United States.

About Correvio Pharma Corp.

Correvio Pharma is a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes brands for the in-hospital, acute care market segment. The company's portfolio of approved and marketed brands includes: Xydalba (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, and Esmocard and Esmocard Lyo (esmolol hydrochloride), a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications.

References

(1) C.T. January et. al.; 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J AM Coll Cardiol. 2014;34:e1-e76;

(2) D. Mozaffarian et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-60;

(3) S. Zhang et. al. Atrial fibrillation in mainland China: epidemiology and current management. BMJ Heart. 2009;95:1052-1055. doi:10.1136/hrt.2008.146589;

(4) A.J. Camm et al. Guidelines for the management of atrial fibrillation, The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.

We seek Safe Harbor.